Pim kinases in hematological malignancies: where are we now and where are we going?

  title={Pim kinases in hematological malignancies: where are we now and where are we going?},
  author={Patrizia Mondello and Salvatore Cuzzocrea and Michael Mian},
  journal={Journal of Hematology \& Oncology},
The proviral insertion in murine (PIM) lymphoma proteins are a serine/threonine kinase family composed of three isoformes: Pim-1, Pim-2 and Pim-3. They play a critical role in the control of cell proliferation, survival, homing and migration. Recently, overexpression of Pim kinases has been reported in human tumors, mainly in hematologic malignancies. In vitro and in vivo studies have confirmed their oncogenic potential. Indeed, PIM kinases have shown to be involved in tumorgenesis, to enhance… 

A review on PIM kinases in tumors

As Pim-1 possesses oncogenic functions and is over expressed in various kinds of cancer diseases, its inhibition provides a new option in cancer therapy and designing new inhibitors of PIMs is now a very active area of research in academic and industrial laboratories.

PIM Kinases in Multiple Myeloma

A comprehensive review on the roles of PIM kinases in myeloma cell survival and proliferation and in the bone marrow microenvironment that supports myelum growth is provided and the promising strategies to exploit PIM as a therapeutic target in malignancy are highlighted.

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

In vivo and in vitro, single-agent INCB053914 inhibited Bcl-2–associated death promoter protein phosphorylation and dose-dependently inhibited tumor growth in acute myeloid leukemia and multiple myeloma xenografts.

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.

The recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models, and these findings support the notion that INCB53914, which is currently in clinical trials in patients with advanced hematologic malignancies, in combination with ruxolitanib may be effective in MPN patients.

Differential Effects of AZD-1208 and SMI-4a, Two Pim-1 Kinase Inhibitors on Primary HAM/TSP and ATL Cells

It is shown that Pim-1 kinase is highly expressed in ATL, as well as in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which underscores the strong therapeutic potential of Pim kinase inhibition for the treatment of HTLV related pathogenesis such as HAM/T SP and ATL 3.

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics

The signaling pathways involved in Pim2 kinase regulation and PIM2 mechanisms in various neoplastic diseases are summarized and the current status and future perspectives for the development of PIM1 kinase inhibitors to combat human cancer are discussed.

Pim-1 kinase as cancer drug target: An update.

The aim of the present updated review is to provide brief information regarding networks of Pim-1 kinase and focus on its recent advances as a novel drug target.

Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression

In vivo, the therapeutic nanoparticle-mediated delivery of PIM2 siRNA led to profound anti-tumor effects in a liver cancer xenograft mouse model, and the potential of targeted therapies based on the specific inhibition of Pim2 in liver cancer is emphasized.



Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

The developed a potent and specific pan-PIM inhibitor, LGB321, which is active on PIM2 in the cellular context and shows that it synergizes with cytarabine in an AML xenograft model, which strongly support the development of Pan-P IM inhibitors to treat hematologic malignancies.

Abstract 2826: Preclinical development of a Pim kinase inhibitor for cancer treatment

Pim kinases were identified as the crucial downstream effectors various important oncogenes like Jak, FLT3 or Ras kinases. Multiple targets phosphorylated by Pim kinases, such as 4EBP1, p21Waf,

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.

It is shown that PIM2 kinase inhibition is a rational approach in DLBCL treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification.

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Pim kinases are not only essential in the hematopoietic lineage cell development, but also important in HSC expansion, self-renewal, and long-term repopulation.

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.

Data suggest that SGI-1776 mechanism in AML involves Mcl-1 protein reduction, and Pim kinase inhibition may be a new strategy for AML treatment.

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

The correlation of nuclear PIM1 expression with disease stage and the modest response to small-molecule inhibitors suggests that PIM kinases are progression markers rather than primary therapeutic targets in DLBCL.

For better or for worse: the role of Pim oncogenes in tumorigenesis

The physiological functions and oncogenic activities of Pim kinases are discussed and potential targets for highly specific and selective drugs with favourable toxicity profiles are discussed.

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

Findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance.

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

It is demonstrated that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T-ALL) being highly sensitive.